S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis
An erratum to this article was published (Arthritis Res Ther, 31 Aug 2024 ↗)
Authors' conclusion
Lower baseline levels of S100A8/9 and S100A12 proteins predicted better response to abatacept treatment than higher levels and may serve as early predictive biomarkers in pJIA.
Study context
- Population
- Patients with active pJIA receiving subcutaneous abatacept158 with biomarker samples
- Participants
- 219 patients
- Comparison
- Lower vs higher baseline S100A8/9 and S100A12 levels
- Primary endpoint
- Association between baseline biomarker levels and JIA-ACR responses or baseline disease activity (JADAS27-CRP)
Methodological detailsexploratory analysis
- Exploratory analysis
Primary result
As reported in the abstract
Odds of response with lower baseline biomarker levels
Odds ratio (95% CI)
Lower S100A8/9JIA-ACR90, month 4
2.54(1.25–5.18)
Lower S100A8/9JIA-ACR100, month 4
3.72(1.48–9.37)
Lower S100A8/9JIA-ACR ID, month 4
4.25(2.03–8.92)
Lower S100A8/9JADAS27-CRP ID, month 4
2.34(1.02–5.39)
Lower S100A8/9JIA-ACR ID, month 16
3.01(1.57–5.78)
Lower S100A12JIA-ACR90
2.52(1.23–5.13)
Lower S100A12JIA-ACR100
3.68(1.46–9.28)
Lower S100A12JIA-ACR ID
3.66(1.76–7.61)
Lower S100A12JIA-ACR90, month 16
2.03(1.07–3.87)
Lower S100A12JIA-ACR100, month 16
2.14(1.10–4.17)
Lower S100A12JIA-ACR ID, month 16
4.22(2.15–8.29)
Further findings
Biomarker change, baseline to month 4, in JIA-ACR90/100/inactive disease (ID) responders
- Decreases in S100A8/9 and S100A12 generally exceeded 50%
Original publication
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis. Arthritis Res Ther. Published 25 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →